Mountain Valley MD (CSE: MVMD) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling with news the company will be conducting a Bio-Safety Level 4 lab study of COVID-19 viral clearance to prove out the Company’s solubilized Ivermectin technology versus commercially available oral form in the time and efficacy in viral clearance.
Farber telling Proactive what that means while Hancock talks about the timing of the study and how excited they are to be doing this one of the kind study.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HERE
